Amylin and Alkermes shine in drug-stocks trading

Amylin and Alkermes shine in early drug-stock trading Friday, fueled by positive news about their diabetes drug candidate Bydureon.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.